Actualités UCB SA - UCB | Actions Euronext

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant...

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe...

UCB Convocation à l'Assemblée Générale des Actionnaires 2024

UCB Convocation à l'Assemblée Générale des Actionnaires 2024 CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil...

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global...

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023 CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’Administration...

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage...

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022 UCB -Société AnonymeAllée de la Recherche 60, 1070 Bruxellesn°...

UCB SA/NV - Convening notice annual shareholders meeting

UCB SA/NV - Convening notice annual shareholders meeting Unofficial English translation – For convenience purposes only UCB SA/NV - Public...

UCB SA/NV : Convening notice to the general meeting of shareholders

UCB SA/NV : Convening notice to the general meeting of shareholders Unofficial English translation – For convenience purposes only UCB...

UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels

UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels Unofficial English translation...

Forums

Afficher les forums

Ucb (Ucb - Bel 20)	5
UCB (Euronext Bruxelles)	7

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB SA (UCB)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCB Actualités

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convocation à l'Assemblée Générale des Actionnaires 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

UCB SA/NV - Convening notice annual shareholders meeting

UCB SA/NV : Convening notice to the general meeting of shareholders

UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB SA (UCB) Actualités

UCB SA (UCB)

Outils de qualité professionnelle, pour des investisseurs individuels.

UCB Actualités

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convocation à l'Assemblée Générale des Actionnaires 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

UCB SA/NV - Convening notice annual shareholders meeting

UCB SA/NV : Convening notice to the general meeting of shareholders

UCB SA/NV: Convening Notice to attend the general meeting of shareholders to be held at Bluepoint Brussels

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités